Parkinson’s Disease Medications Availability in Each Philippine Region
Objective: This study aimed to enumerate the different Parkinson’s disease medications in the Philippines and describe the distribution and availability among the 17 regions of…Determinant factors of treatment adherence in Parkinson’s disease
Objective: To determine factors predicting treatment adherence in patients with idiopathic Parkinson’s disease. Background: Parkinson’s disease is the second most common cause of neurodegenerative disease…Effect of pharmacist-led interventions on motor symptoms and quality of life in Parkinson’s patients: A pilot study
Objective: Improvement of on-off symptoms in ambulatory patients with Parkinson's disease (PD) by introduction of a multi-faceted medication optimization program. This consisted of a patient…Characteristics of patients initiating droxidopa for the treatment of neurogenic orthostatic hypotension (nOH)
Objective: To understand the characteristics of patients initiating droxidopa therapy for the treatment of neurogenic orthostatic hypotension (nOH). Background: nOH is defined as a fall…Efficacy and feasibility study of the Medido eletronic medication dispenser in Parkinson’s disease: A multicentre randomized controlled trial
Objective: The aim of this randomized controlled study was to assess the effect of the electronic medication dispenser, Medido, on physical limitations in PD. Background:…Patient-centered educational intervention using hand-held electronic devices
Objective: To examine feasibility, usability and initial efficacy of an e-learning intervention, using an interactive tablet-based slideshow with audio/video and quizzes. Background: Mobile tablet and…The novel COMT-inhibitor ODM-104 and optimized carbidopa in combination with modified release levodopa reduce levodopa fluctuation and increase minimum concentrations in healthy subjects, when compared to the standard carbidopa/levodopa/entacapone combination
Objective: To evaluate the plasma pharmacokinetics (PK) of orally administered modified release (MR) levodopa in combination with the aromatic L-amino acid decarboxylase inhibitor carbidopa and…Parkinson’s syndrome as possible manifestation of lamina quadrigemina tumor or inflammation
Objective: Objective of this report is to discuss the case of Parkinson's syndrome (PS) in 22 y.o. patient on the background of the pathological process…Outpatient management of Parkinson’s disease: A review of medication changes made to address both motor and non-motor symptoms
Objective: To identify reasons for medication changes at outpatient movement disorder clinics and determine outcome of these changes at next clinic visit. Background: Parkinson's disease…Treatment of lipopolysaccharide-induced parkinsonism
Objective: This single case report of levodopa-responsive parkinsonism, caused by an accidental systemic contamination with 10 microgram lipopolysaccharides (LPS) from Salmonella minnesota, describes the treatment…